Across TCGA pan-cancer cohorts, NKAIN2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated NKAIN2 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher NKAIN2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NKAIN2 expression acts as an unfavorable survival marker.

HNSC, SARC, and LUSC are the cancer types where NKAIN2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.143	0.661	<.001	51	view →
SARC	DFS	Median	All	0.173	0.616	<.001	9	view →
LUSC	OS	Median	All	0.196	0.724	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: NKAIN2 tumor-vs-normal RNA expression · all NKAIN2 data types